KRAS and neoplasm: Despite the absence of microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB), the patient with <i>TP53/KRAS</i> mutation achieved a significantly long PFS of 17 months, and the benefit is still ongoing.